| Literature DB >> 31494824 |
Junhong Yu1,2, Tatia M C Lee3,4,5,6.
Abstract
While strong cross-sectional evidence supported the use of fornix microstructure as a marker for detecting Alzheimer's disease (AD), longitudinal data remains inconclusive on the sequential nature of fornix microstructure abnormalities and AD progression. An unequivocal longitudinal relationship between fornix microstructure and markers of AD progression -memory impairment and hippocampal atrophy, must be established to validate fornix microstructure as a marker of AD progression. We included 115 participants from the Alzheimer's Disease Neuroimaging Initiative across the non-demented AD spectrum- defined as those who had at least one AD risk marker at baseline (e.g., mild cognitive impairment (MCI) due to AD diagnosis, amyloid or ApoE4 positivity) and/or 'cognitively normal individuals who converted to MCI due to AD or AD, with structural and diffusion tensor imaging scans at baseline and two years follow-up. Hippocampal volumes (HV), fractional anisotropy (FA) and mean diffusivity (MD) in the fornix were extracted. Memory was indexed via composite scores of verbal memory tests. Structural equation models tested the bidirectional cross-lagged effects of fornix microstructure, memory, and HV. Impaired memory and smaller HV at baseline significantly predicted worse fornix microstructure (decreased FA and increased MD) two years later. Baseline fornix microstructure was not associated with subsequent changes in memory and HV. Fornix microstructure is compromised likely at a later stage, where significant decline in memory and hippocampal atrophy have occurred. This limits the utility of fornix microstructure in the early detection of AD. Our findings inform the possible pathophysiology and refined the use of AD neural markers.Entities:
Keywords: ADNI; Alzheimer’s disease; Fornix; Hippocampus; Longitudinal; Memory
Year: 2020 PMID: 31494824 PMCID: PMC7647989 DOI: 10.1007/s11682-019-00183-8
Source DB: PubMed Journal: Brain Imaging Behav ISSN: 1931-7557 Impact factor: 3.978
Fig. 1Venn diagram showing the included participants with the various AD-spectrum related characteristics. CSF Aβ = Cerebrospinal fluid amyloid-beta; AD = Alzheimer’s disease; MCI = Mild cognitive impairment
Characteristics of included participants
| Mean (SD)/Frequency (%) | |
|---|---|
| Agebaseline | 73.1 (6.9) |
| Gender | |
| Male | 61 (53.0%) |
| Female | 54 (47.0%) |
| Years of education | 16.0 (2.6) |
| Neurocognitive diagnosis | |
| Cognitively normal at baseline | 47 (40.9%) |
| Remained at cognitively normal at follow-upa | 34 (72.3%) |
| Converted to MCI due to AD at follow-up | 10 (21.3%) |
| Converted to AD at follow-up | 3 (6.4%) |
| MCI due to AD at baseline | 68 (59.1%) |
| Remained at MCI due to AD at follow-up | 52 (76.5%) |
| Converted to AD at follow-up | 16 (23.5%) |
| MMSE scoresbaseline | 28.0 (1.8) |
| Ethnicity | |
| Caucasian | 107 (93.0%) |
| Native American | 1 (.9%) |
| Asian American | 3 (2.6%) |
| African American | 4 (3.5%) |
SD, standard deviation. MCI due to AD = Mild cognitive impairment due to Alzheimer’s disease
aAmong these stable cognitively normal participants, 27 are CSF Aβ positive and 21 are APOε4 positive
Correlation matrix of all studied continuous variables
| Variable | Age baseline | Edu. | Mem. baseline | Mem. follow-up | FA baseline | FA follow-up | MD baseline | MD follow-up | HV baseline |
|---|---|---|---|---|---|---|---|---|---|
| Agebaseline | |||||||||
| Edu. | −.08 | ||||||||
| Mem.baseline | −.11 | .10 | |||||||
| Mem.follow-up | −.06 | .05 | .86*** | ||||||
| FAbaseline | −.48*** | .01 | .23* | .18 | |||||
| FAfollow-up | −.56*** | −.01 | .31** | .26** | .87*** | ||||
| MDbaseline | .53*** | .15 | −.23* | −.19 | −.89*** | −.85*** | |||
| MDfollow-up | .56*** | .10 | −.28** | −.24* | −.82*** | −.93*** | .93*** | ||
| HVbaseline | −.49*** | <.01 | .38*** | .40*** | .59*** | .68*** | −.59*** | −.65*** | |
| HVfollow-up | −.49*** | .03 | .43*** | .43*** | .60*** | .71*** | −.60*** | −.67*** | .93*** |
Edu, Education in years; Mem, memory composite scores (ADNI-MEM); FA, Fractional Anisotropy of fornix; MD, Mean Diffusivity of fornix; HV, Hippocampal volume (adjusted for intracranial volume). *p < .05; **p < .01; ***p < .001
Descriptive statistics of longitudinal measures
| ADNI-MEM | Fornix | T1 Structural | ||||||
|---|---|---|---|---|---|---|---|---|
| Valid N | M (SD) | Valid N | FA | MD (10−3 mm2/s) | Valid N | HV (cm3) | TIV (cm3) | |
| Baseline | 115 | .417 (.693) | 98 | .350 (.048) | 1.399 (.202) | 112 | 7.243 (1.031) | 1477 (131) |
| Follow-up | 115 | .339 (.897) | 98 | .334 (.053) | 1.433 (.216) | 112 | 6.926 (1.177) | 1479 (135) |
| Follow-up - baseline | 115 | −.078 (.465) | 98 | −.016(.026) | .034 (.079) | 112 | −.316 (.145) | 2.521 (26.3) |
ADNI-MEM, memory composite scores; FA, Fractional Anisotropy; MD, Mean Diffusivity; HV, Hippocampal volume (adjusted for intracranial volume); TIV, intracranial volume; M, Mean; SD, Standard Deviation
Fit indices of all examined SEM models
| Model | CFI | SRMR |
|---|---|---|
| Fornix FA ↔ ADNI-MEM | .993 | .039 |
| Fornix MD ↔ ADNI-MEM | .994 | .039 |
| Fornix FA ↔ HV | .950 | .095 |
| Fornix MD ↔ HV | .960 | .093 |
CFI, Comparative Fit Index; SRMR, Standardized Root Mean Square residual; FA, Fractional Anisotropy; MD, Mean Diffusivity; HV, Hippocampal volume (adjusted for intracranial volume); ADNI-MEM, memory composite scores
Fig. 2Robust Maximum likelihood estimation of the cross-lagged effects between extracted regions of interest and ADNI-MEM, with age, sex and education included as covariates. Straight lines represent regression paths. Curve line represents residual covariance. FA = Fractional Anisotropy; MD = Mean Diffusivity; β = standardized coefficients; SE = Standard Error
Fig. 3Robust Maximum likelihood estimation of the cross-lagged effects between extracted regions of interest and hippocampal volume, with age, sex and education included as covariates. Straight lines represent regression paths. Curve line represents residual covariance. FA = Fractional Anisotropy; MD = Mean Diffusivity; HV = Hippocampal volume (adjusted for intracranial volume); β = standardized coefficients; SE = Standard Error